2,2'-(3-Bromothiophene-2,5-diyl)bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolane), 98%, 10g

6-chloro-2-(2-thienyl)quinoline-4-carboxylic acid, 95.0%, 1g

Objectif Plan PLi 2x/0.05 IOS corrigé à l'infini, pas de correction du verre de protection. Distance de travail 18,3 mm

(4-Oxo-4-phenyl-butyl)-carbamic acid tert-butylester, 98.0%, 1g

(1H-PYRAZOL-3-YL)-ACETIC ACID ETHYL ESTER, 95.0%, 25g

(3-Methoxybenzyl)hydrazine hydrochloride, 95.0%, 500mg

2-(2-Chloro-acetylamino)-4-(5-methyl-furan-2-yl)-thiophene-3-carboxylic acid ethyl ester, 95.0%, 1g

Methyl (S)-4-benzyl-5-oxo-morpholine-3-carboxylate, 97.0%, 10g

2-Methyl-4,6-dimethoxypyrimidine, 97.0%, 100g

3,4,5,6,7,8-hexahydroquinazolin-4-one, 99.98%, 5g

N'-[1-Cyclopenylamino-2-phenylidene]hydrazinecarboxylic acid tert-butyl ester, 95.0%, 1g

NON-8-YNOIC ACID, 95%, 100mg

3-Chlorophenethyl alcohol, 95.0%, 100g